At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis
23rd July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now